Skip to main content

Akihiko Shimomura, MD

Akihiko Shimomura, MD
Conference Coverage
01/03/2024
Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...
Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...
Akihiko Shimomura, MD, discussed...
01/03/2024
Oncology